HighPassBio

Executive Summary

HighPassBio is a Seattle-based private biotechnology company founded in 2018, dedicated to developing novel T-cell receptor (TCR) therapies for cancer. The company's proprietary platform enables engineering of T-cells that recognize and eliminate cancer cells by targeting intracellular antigens, offering potential for treating both solid tumors and hematological malignancies. While still in early stages (preclinical or early clinical), HighPassBio's approach differentiates itself from CAR-T by targeting a broader range of intracellular targets, which could expand treatable patient populations. The company benefits from Seattle's rich biotech ecosystem and has not yet disclosed funding rounds or valuation, suggesting it may be operating in stealth or early development. If successful, HighPassBio could address key limitations of current immunotherapies, particularly in solid tumors where T-cell infiltration and antigen heterogeneity pose challenges.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead TCR Program30% success
• Q4 2026Preclinical Data Presentation at Major Conference (e.g., SITC or ASCO)60% success
• Q3 2026Initial Series A or Seed Funding Announcement50% success